World Market for Sexual Disorders, 2005-2012, The

Traversing New Frontiers in Sexual Chemistry

Publication Date January 2006
ISBN n/a
Pages 122
Tables 26
Figures 7

Print £825 $1295

 Add to Basket

PDF £795 $1250

Single user

 Add to Basket

PDF £4600 $7215

Companywide user

 Add to Basket

The report provides a detailed analysis of the sexual disorders therapy area to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development, with promising agents further discussed from commercial and drug development perspectives. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into potential top-performing products. Therapy area forecasting to 2020 also enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

REPORT HIGHLIGHTS AND KEY FINDINGS
  • The current market for drugs to treat sexual disorders is estimated at US$3.8 billion, which is forecast to increase 74% to US$6.6 billion by 2012
  • Critical analysis of marketed sexual dysfunction drugs related to erectile dysfunction and androgen deficiency
  • Analysis of over 20 key marketed and pipeline products and inclusion of 43 R&D candidates identified in preclinical to clinical stages of development
  • Sales estimates (US$) to 2012 for leading products
  • Strategic insights for life-cycle optimization and product development
  • Commercial evaluation of leading sexual disorder pharmacotherapies
  • Trend analysis of industry events and activities over past 2 years
  • Detailed R&D themes and clusters by therapy area
  • Data generation on sector and market values between 2004 and 2012 and therapy area forecasts by 2020 (US$)
  • High revenue-yielding prospects identified with projected sales estimations
  • R&D pipeline positioning for novel candidates
  • Market insights for product development and drug promotion

    WHAT CAN I LEARN FROM THIS REPORT?
  • Which drugs are the current and potential future market leaders in the sexual dysfunction therapy domain
  • Insights into utility of androgenic drugs to treat male andropause and female sexual disorders
  • What impact new drug approvals will have on the sexual medicine drug market
  • Which premarket drugs are identified as high-value products
  • Which companies are developing drugs for male and female sexual disorders
  • Sales predictions to 2012 for male sexual dysfunction therapies
  • How will newcomers affect the product positioning of market leaders
  • What are the niche market opportunities in sexual dysfunction
  • What the future outlook may hold for sexual disorder pharmacotherapies
    How companies are expanding the global sexual medicine market through new indications and therapeutic switching
  • Which molecules and compounds are main R&D clusters in sexual dysfunction drug development
  • Which of the pipeline candidates are identified as top prospects over the next decade and to 2020

    COMPANIES MENTIONED IN REPORT
    ABBOTT LABORATORIES
    ACRUX
    ALZA
    AMILAR PHARMA
    ARDANA BIOSCIENCES
    ASCEND THERAPEUTICS
    ASTELLAS PHARMA
    BAYER
    BIOSANTE
    BIOACCELERATE
    CELLEGY PHARMACEUTICALS
    COLUMBIA LABORATORIES
    DONG-A PHARMTECH
    GLAXOSMITHKLINE
    GTX
    JOHNSON & JOHNSON
    IPSEN
    LIGAND
    LILLY ICOS
    MACROCHEM
    NASTECH
    ORGANON
    PALATIN TECHNOLOGIES
    PFIZER
    PLETHORA SOLUTIONS
    PROCTOR & GAMBLE
    SCHERING
    SCHWARZ PHARMA
    SENETEK
    SOLVAY
    SURFACE LOGIX
    TAP PHARMACEUTICALS
    VECTURA
    VIVUS
    WATSON PHARMACEUTICALS
    ZONAGEN

    • Executive Summary


    Objectives of the Report

    Research Methodology

    Chapter 1 Introduction to Sexual Disorders

    Sexual Disorders
    Prevalence of Sexual Dysfunction
    Male Sexual Disorders
    Sexual Desire Disorders
    Male Erectile Dysfunction
    Normal Erectile Function
    Psychological Aspects of Male Erectile Dysfunction
    Prevalence of Male Erectile Dysfunction
    Therapeutics for Male Erectile Dysfunction
    Priapism
    Peyronie’s disease
    Disorders of Ejaculation
    Premature Ejaculation
    Retarded Ejaculation
    Retrograde Ejaculation

    Female Sexual Dysfunction
    Prevalence of Female Sexual Dysfunction
    Specific Female Sexual Dysfunction Disorders
    Disorders of Desire
    Disorders of Arousal
    Disorders of Lubrication
    Persistent Sexual Arousal Syndrome
    Disorders of Orgasm
    Pain Disorders
    Dyspareunia
    Vulvodynia
    Vaginismus

    Chapter 2 The Sexual Disorders Pharmacotherapy Market

    Market Data Synopsis - Sexual Disorders
    Sexual Disorders: Market Overview
    Market Analysis for Sexual Disorder Pharmacotherapeutics
    Testosterone Replacement
    Erectile Dysfunction
    Female Sexual Disorders

    Male Sexual Disorders
    Androgen Deficiency and Disorders of Desire
    The Andropause
    Product Market Analysis for Androgen Deficiency and Disorders of Desire
    Columbia Labs/Ardana
    Sales Estimates and Market Outlook
    Organon
    Sales Estimates and Market Outlook
    Schering
    Sales Estimates and Market Outlook
    Solvay Pharmaceuticals
    Sales Estimates and Market Outlook
    Drugs in Research and Development for Androgen Deficiency and Andropause
    Ascend Therapeutics
    Ardana
    GTx
    Androgen Deficiency and Sarcopenia - A High-Growth Market Prospect
    National Institute on Aging
    Anastrozole/Testosterone
    Androgen Supplementation
    Testosterone and Human Growth Hormone
    Zonagen
    Future Considerations for Drugs to Treat Androgen Deficiencies Associated with Sexual Disorders and Andropause

    Erectile Dysfunction
    Uprima/Ixense (Apomorphine) - Abbott/TAP Pharmaceuticals
    Sales Estimates and Market Outlook
    Levitra (Vardenafil) - Bayer/GlaxoSmithKline
    Sales Estimates and Market Outlook
    Cialis (Tadalafil) - Lilly/ICOS
    Sales Estimates and Market Outlook
    Viagra (Sildenafil); Caverject (Alprostadil) - Pharmacia/Pfizer
    Sales Estimates and Market Outlook
    Viridal/Edex (Alprostadil) - Schwarz
    Sales Estimates and Market Outlook
    Invicorp (Phentolamine Mesilate/Vasoactive Intestinal Polypeptide)-
    Senetek/Ardana
    Sales Estimates and Market Outlook
    MUSE (Alprostadil) - Vivus
    Sales Estimates and Market Outlook
    Pipeline Focus - Avanafil
    Future Considerations and Market Outlook for Drugs to Treat
    Erectile Dysfunction
    Pipeline Drugs and Market Prospects in the Sexual Disorder Market
    Erectile Dysfunction Drug Pipeline
    Prograf (Tacrolimus/FK506) - Astellas Pharma
    Alprox-TD (Alprostadil) - NexMed/Schering
    PT-141 - Palatin Technologies/King Pharmaceuticals

    Emerging Sexual Disorder Therapy Areas
    Premature Ejaculation
    Neuronal Mechanism of Premature Ejaculation
    Drugs in Development for Premature Ejaculation
    Dapoxetine - ALZA/Johnson & Johnson
    Investigational Drug - Pfizer
    BIO301 - Enhance Biotech/Bioaccelerate
    NM100061 - NexMed
    Future Considerations and Market Outlook for Drugs to Treat
    Premature Ejaculation

    Female Sexual Disorders
    A High-Growth Market Opportunity?
    Drugs in Development for Female Sexual Disorders
    Intrinsa (Testosterone Patch) - Proctor & Gamble Pharmaceuticals/ Watson Pharma
    Tostrelle (Testosterone Gel) - Cellegy Pharmaceuticals
    Androgel (Testosterone Gel) - Beersheva Mental Health Center, Israel
    LibiGel (Testosterone Gel) - Antares Pharma/Biosante Pharmaceuticals
    PT-141 - Palatin Technologies/King Pharmaceuticals
    Alista (Alprostadil); Testosterone MDTS - Vivus/Acrux
    Femprox Cream (Alprostadil) - NexMed
    Future Considerations and Market Outlook for Drugs to Treat
    Female Sexual Dysfunction

    Chapter 3 Drugs in Research and Development

    Male Sexual Disorders
    Research and Development Overview
    Female Sexual Dysfunction
    Research and Development Overview

    Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining

    Sexual Disorders: Therapy Area Forecasts
    Market Share of Male Sexual Disorder Market
    Comparative Analysis: Product Sales
    Prospect Mining
    Androgen Deficiency/Testosterone Replacement
    Erectile Dysfunction and Premature Ejaculation
    Female Sexual Dysfunction
    Therapy Area Forecasts: 2012 and 2020

    Chapter 5 Report Synopsis

    Male Sexual Disorders - Key Data Points
    Female Sexual Disorders - Key Data Points

    Reference Sources

    List of Tables

    Table 1.1 Male and Female Sexual Dysfunction Disorders
    Table 1.2 Medical and Surgical Conditions Associated with Erectile Dysfunction
    Table 1.3 Therapeutic Options for Erectile Dysfunction
    Table 2.1 Global Sales (US$) & Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012
    Table 2.2 Marketed Drugs for Androgen Deficiency and Erectile Dysfunction, 2005
    Table 2.3 Symptoms of Andropause
    Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Striant, 2005-2012
    Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Organon’s Androgen Replacement Therapy Products, 2005-2012
    Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Schering’s Andrology Product Portfolio, 2005-2012
    Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Androgel, 2005-2012
    Table 2.8 Drugs in Development for Androgen Deficiency and Andropause, 2005
    Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Uprima/Ixense, 2005-2012
    Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Levitra, 2005-2012
    Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Cialis, 2005-2012
    Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Pfizer’s Erectile Dysfunction Product Portfolio, 2005-2012
    Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Viridal/Edex, 2005-2012
    Table 2.14 Estimated Sales (US$) and Annual Growth (%) of Invicorp, 2005-2012
    Table 2.15 Estimated Sales (US$) and Annual Growth (%) of Muse, 2005-2012
    Table 2.16 Drugs in Development for Male Erectile Dysfunction, 2005
    Table 2.17 Drugs in Development for Premature Ejaculation, 2005
    Table 2.18 Drugs in Development for Female Sexual Dysfunction, 2005
    Table 3.1 Drugs in Development for Male Androgen Deficiency and Andropause, 2005
    Table 3.2 Drugs in Development for Male Erectile Dysfunction and Premature Ejaculation, 2005
    Table 3.3 Drugs in Development for Female Sexual Dysfunction, 2005
    Table 4.1 Global Market for Male Sexual Disorders (US$m), 2004-2012
    Table 4.2 Therapy Area Forecasts for the Global Sexual Disorders Drug Market: 2012 and 2020

    List of Figures

    Figure 2.1 Estimated Sales (US$) and Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012
    Figure 2.2 Estimated Growth and Global Market Share of Leading Drugs for Male Sexual Disorders, 2005 & 2012
    Figure 4.1 Therapy Area Forecasts for Male Testosterone Replacement and Erectile Dysfunction, 2005 & 2012 (US$m)
    Figure 4.2 Market Share of Male Testosterone Replacement (Desire/Arousal Conditions) and Erectile Dysfunction Therapy Areas, 2005 & 2012
    Figure 4.3 Comparative Analysis of Leading Testosterone Replacement Therapies and Erectile Dysfunction Products, 2004-2012 (US$m)
    Figure 4.4 Key Testosterone Replacement Drug Prospects in the Development Pipeline, 2005
    Figure 4.5 Key Erectile Dysfunction and Premature Ejaculation Drug Prospects in the Development Pipeline, 2005